A Study of JNJ-1761981 in Participants With Solid Tumors

Part of paid clinical trials in The Bronx, New York.

Sponsor
Johnson & Johnson Enterprise Innovation Inc.
Study ID
NCT07525141
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JNJ-1761981 — DRUG
    JNJ-1761981 will be administered intratumorally.
  • Cetrelimab — DRUG
    Cetrelimab will be administered intravenously.

Study Details

The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.

Key Dates

Start date
May 26, 2026
Status verified
Jun 2026
Primary completion
Jan 12, 2028
Completion
Jan 31, 2029

Study Design

Enrollment
66 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1: Dose Escalation
    Participants will receive JNJ-1761981 intratumorally to determine a safe and tolerable total JNJ-1761981 dose.
  • Experimental: Part 2: Dose Expansion
    Participants in Cohort A will receive JNJ-1761981 at specified volumetric doses. Participants who receive more than 1 dose of JNJ-1761981 may receive optional systemic therapy with cetrelimab at the discretion of the treating physician.

Primary Outcome Measure

Part 1: Number of Participants with Adverse Events (AE) by Severity [ Time Frame: Up to approximately 2 years 10 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Montefiore Medical CenterThe BronxNew York10467-
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in The Bronx, NY

By research site
Montefiore Medical Center· The Bronx, NYMD Anderson Cancer Center· Houston, TX

Related Studies